What is Genfit Sa share price today?

Genfit Sa (GNFT) share price today is {{live_price}}.

Can Indians buy Genfit Sa shares?

Yes, Indians can invest in the Genfit Sa (GNFT) from India. With INDmoney, you can buy Genfit Sa at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Genfit Sa at zero transaction cost.

How can I buy Genfit Sa shares from India?

It is very easy to buy Genfit Sa from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Genfit Sa be purchased?

Yes, you can buy fractional shares of Genfit Sa with INDmoney app.

What are the documents required to start investing in Genfit Sa stocks?

To start investing in Genfit Sa, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Genfit Sa

Today’s highest price of Genfit Sa (GNFT) is {{1_rba_end}}. Today’s lowest price of Genfit Sa (GNFT) is {{1_rba_st}}.

What is today's market capitalisation of Genfit Sa

Today's market capitalisation of Genfit Sa GNFT is 211.0M

What is the 52 Week High and Low Range of Genfit Sa

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Genfit Sa is down from its 52 Week High?

Genfit Sa (GNFT) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Genfit Sa is up from its 52 Week low?

Genfit Sa (GNFT) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Genfit Sa?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Genfit Sa

Mr. Jean-Francois Mouney is the current Chief Executive Officer (CEO) of Genfit Sa.

Home>
US Stocks>
Genfit Sa

Genfit Sa (GNFT)

$4.15

-0.04

(-0.95%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

$3.89
$4.24
$4.15
6.36%
Downside
Day's Volatility :8.35%
Upside
2.12%
$2.89
$6.05
$4.15
30.28%
Downside
52 Weeks Volatility :52.17%
Upside
31.4%

Returns

Period	Genfit Sa	Index (Russel 2000)
3 Months	-23.57%	0.0%
6 Months	16.41%	0.0%
1 Year	7.79%	0.0%
3 Years	1.22%	-22.3%

Highlights

Market Capitalization	211.0M
Book Value	$1.37
Earnings Per Share (EPS)	-0.64

Profit Margin	-83.79%
Operating Margin TTM	-56.31%

Return On Assets TTM	-9.91%
Return On Equity TTM	-35.57%

Revenue TTM	34.5M
Revenue Per Share TTM	0.69
Quarterly Revenue Growth YOY	37.3%
Gross Profit TTM	26.2M
EBITDA	-29.3M
Diluted Eps TTM	-0.64
Quarterly Earnings Growth YOY	0.0

EPS Estimate Current Year	0.0
EPS Estimate Next Year	0.0
EPS Estimate Current Quarter	0.0
EPS Estimate Next Quarter	0.0

Analyst Recommendation

Buy

92%Buy

7%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Genfit Sa(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Company Financials

	FY18	Y/Y Change
Revenue	78.5K	↓ 41.53%
Net Income	-90.5M	↑ 35.69%
Net Profit Margin	-115.2K%	↓ 65583.42%

	FY19	Y/Y Change
Revenue	34.3M	↑ 44594.2%
Net Income	-72.4M	↓ 18.08%
Net Profit Margin	-211.24%	↑ 115036.59%

	FY20	Y/Y Change
Revenue	930.5K	↓ 97.52%
Net Income	-123.1M	↑ 55.38%
Net Profit Margin	-13.2K%	↓ 13020.26%

	FY21	Y/Y Change
Revenue	90.5M	↑ 10366.54%
Net Income	76.0M	↓ 166.45%
Net Profit Margin	84.0%	↑ 13315.5%

	FY22	Y/Y Change
Revenue	21.4M	↓ 74.78%
Net Income	-25.1M	↓ 135.27%
Net Profit Margin	-117.45%	↓ 201.45%

	FY23	Y/Y Change
Revenue	31.2M	↑ 41.45%
Net Income	-31.5M	↑ 21.81%
Net Profit Margin	-101.15%	↑ 16.3%

	Q1 FY23	Q/Q Change
Revenue	7.6M	↑ 23.97%
Net Income	-10.4M	-
Net Profit Margin	-138.0%	-

	Q2 FY23	Q/Q Change
Revenue	11.5M	↑ 51.96%
Net Income	-20.9M	↑ 100.0%
Net Profit Margin	-181.62%	↓ 43.62%

	Q3 FY23	Q/Q Change
Revenue	3.0M	↓ 75.46%
Net Income	-4.3M	↓ 80.72%
Net Profit Margin	-142.65%	↑ 38.97%

	Q1 FY24	Q/Q Change
Revenue	17.1M	↑ 19.75%
Net Income	-8.0M	-
Net Profit Margin	-47.06%	-

	FY18	Y/Y Change
Total Assets	261.0M	↓ 21.73%
Total Liabilities	237.2M	↑ 10.36%

	FY19	Y/Y Change
Total Assets	344.3M	↑ 35.03%
Total Liabilities	250.9M	↑ 8.27%

	FY20	Y/Y Change
Total Assets	241.6M	↓ 35.9%
Total Liabilities	261.2M	↓ 4.88%

	FY21	Y/Y Change
Total Assets	318.5M	↑ 41.84%
Total Liabilities	183.8M	↓ 24.28%

	FY22	Y/Y Change
Total Assets	228.1M	↓ 23.49%
Total Liabilities	128.1M	↓ 25.59%

	FY23	Y/Y Change
Total Assets	173.3M	↓ 19.58%
Total Liabilities	105.9M	↓ 12.47%

	Q4 FY22	Q/Q Change
Total Assets	228.1M	-
Total Liabilities	128.1M	-

	Q1 FY23	Q/Q Change
Total Assets	207.5M	↓ 10.04%
Total Liabilities	127.8M	↓ 1.34%

	Q2 FY23	Q/Q Change
Total Assets	210.3M	↑ 0.0%
Total Liabilities	129.5M	↑ 0.0%

	Q3 FY23	Q/Q Change
Total Assets	173.9M	↓ 10.33%
Total Liabilities	105.9M	↓ 11.28%

	Q4 FY23	Q/Q Change
Total Assets	189.7M	↑ 0.0%
Total Liabilities	115.5M	↑ 0.0%

	Q1 FY24	Q/Q Change
Total Assets	173.3M	↓ 0.3%
Total Liabilities	105.9M	↑ 0.0%

	FY18	Y/Y Change
Operating Cash Flow	-63.8M	↑ 12.49%
Investing Cash Flow	-4.5M	↑ 35.21%
Financing Cash Flow	-7.4M	↓ 103.74%

	FY19	Y/Y Change
Operating Cash Flow	-53.0M	↓ 14.98%
Investing Cash Flow	363.4K	↓ 108.2%
Financing Cash Flow	129.9M	↓ 1893.98%

	FY20	Y/Y Change
Operating Cash Flow	-117.2M	↑ 102.12%
Investing Cash Flow	-1.2M	↓ 395.41%
Financing Cash Flow	-10.0M	↓ 107.06%

	FY21	Y/Y Change
Operating Cash Flow	112.9M	↓ 203.68%
Investing Cash Flow	-3.8M	↑ 249.59%
Financing Cash Flow	-10.1M	↑ 7.99%

	Q3 FY22	Q/Q Change
Operating Cash Flow	-12.6M	↓ 74.1%
Investing Cash Flow	1.3M	↓ 1447.74%
Financing Cash Flow	-921.5K	↑ 2.05%

	Q4 FY22	Q/Q Change
Operating Cash Flow	-12.5M	↓ 0.26%
Investing Cash Flow	1.3M	↑ 0.0%
Financing Cash Flow	-882.0K	↓ 4.29%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-12.5M	↑ 0.0%
Investing Cash Flow	1.3M	↑ 0.0%
Financing Cash Flow	-882.0K	↑ 0.0%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-25.8M	↑ 106.13%
Investing Cash Flow	1.3M	↑ 0.0%
Financing Cash Flow	-995.0K	↑ 12.81%

Technicals Summary

Sell

Neutral

Buy

Genfit Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Genfit Sa	2.22%	16.41%	7.79%	1.22%	-75.72%
Regeneron Pharmaceuticals, Inc.	5.97%	16.25%	37.11%	69.18%	305.56%
Novo Nordisk A/s	9.99%	-3.52%	34.24%	158.74%	417.73%
Alnylam Pharmaceuticals, Inc.	-5.15%	64.67%	22.72%	31.08%	198.44%
Vertex Pharmaceuticals Incorporated	0.45%	14.0%	36.06%	143.5%	167.72%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Genfit Sa	NA	NA	NA	0.0	-0.36	-0.1	NA	1.37
Regeneron Pharmaceuticals, Inc.	29.93	29.93	1.54	45.05	0.17	0.08	NA	261.41
Novo Nordisk A/s	44.01	44.01	1.98	3.44	0.89	0.23	0.01	25.24
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-2.55	-15.01	0.02	NA	-0.02
Vertex Pharmaceuticals Incorporated	32.84	NA	0.57	0.32	-0.03	0.13	NA	57.26

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Genfit Sa	Buy	$211.0M	-75.72%	NA	-83.79%
Regeneron Pharmaceuticals, Inc.	Buy	$124.7B	305.56%	29.93	32.04%
Novo Nordisk A/s	Buy	$585.3B	417.73%	44.01	34.84%
Alnylam Pharmaceuticals, Inc.	Buy	$32.3B	198.44%	NA	-3.11%
Vertex Pharmaceuticals Incorporated	Buy	$120.9B	167.72%	32.84	-4.74%

Insights on Genfit Sa

Increasing Revenue
Revenue is up for the last 3 quarters, 2.81M → 17.08M (in $), with an average increase of 48.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -4.01M → -8.03M (in $), with an average decrease of 100.0% per quarter
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 29.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 68.0%